MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares

New ordinary shares will dilute existing holders, with further issuance possible through the underwriter’s option.

Rhea-AI Summary

MediWound (Nasdaq: MDWD) entered into a firm-commitment underwriting agreement with H.C. Wainwright for an offering expected to raise approximately $15 million. The underwriter agreed to purchase 1,200,000 ordinary shares at a public offering price of $12.50 per share, less underwriting discounts and commissions. Expected gross proceeds exclude those deductions and offering expenses and assume no exercise of the additional-share option.

The underwriter received a 30-day option to purchase up to 180,000 additional ordinary shares at the same public price, less underwriting discounts and commissions. Closing is expected on or about November 5, 2026, subject to customary closing conditions. MediWound intends to use net proceeds for working capital and general corporate purposes.

1 point · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.The firm-commitment offering is expected to raise approximately $15 million gross, excluding the underwriter’s option. 8.7% of market cap

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.1,200,000 new ordinary shares at a public price of $12.50 each will dilute existing holders.
• Minor point. Forward-looking: it has not happened yet and may not happen.The 30-day option permits up to 180,000 additional shares at $12.50 each, creating potential further dilution.
• Minor point. Forward-looking: it has not happened yet and may not happen.Underwriting discounts, commissions and offering expenses will reduce proceeds available to MediWound.

News Explained

The agreed sale of 1,200,000 ordinary shares has not closed and remains subject to customary conditions; if completed, the added shares increase the total share count and reduce existing holders’ percentage ownership absent offsets.

Argus 15 min delay 2 alerts

-4.78% vs previous close $12.75 last price 1.0x rel. volume Open Argus

Details

Market Reaction – MDWD

$11.82 – $13.81 Day Range

$164.61M Mkt Cap at Last Price

On Nov 3, the day this news came out, the latest delayed price for MDWD is 4.78% below the previous close. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $12.75.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Expected gross proceeds: Approximately $15 million Ordinary shares: 1,200,000 shares Public offering price: $12.50 per share +2 more

Expected gross proceeds

Approximately $15 million

Before discounts, commissions and offering expenses; assumes no option exercise

Ordinary shares

1,200,000 shares

Firm commitment purchase by the underwriter

Public offering price

$12.50 per share

Less underwriting discounts and commissions

Underwriter option

Up to 180,000 additional shares

30-day option at the public offering price, less discounts and commissions

Expected closing

On or about November 5, 2026

Subject to customary closing conditions

Previous Offering Reports

1 past event · Latest: Sep 29

Same Type 1 event

1. Sep 29

   Registered direct offering

   24h Move

   +0.5%

   Registered direct offering priced 1,734,105 shares at $17.30, with $30 million in gross proceeds.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

bought deal, underwriting agreement, firm commitment basis, shelf registration statement, +1 more

5 terms

bought deal financial

"MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares"

A bought deal is a type of securities offering where an investment bank agrees to purchase the entire share or bond issue from a company up front and then resells it to investors, acting like a wholesaler who guarantees the sale. For investors, it matters because it gives the company fast, certain access to cash while potentially signaling pricing pressure or dilution—meaning the shares may be sold at a discount and existing holders could see their ownership reduced.

underwriting agreement financial

"entered into an underwriting agreement with H.C. Wainwright"

An underwriting agreement is a contract where a company selling new stocks or bonds hires financial firms to buy those securities and resell them to investors. It matters because the agreement sets the offering price, number of securities, fees and which party bears the risk if sales fall short—think of it as a promise that the sale will happen and a roadmap investors can use to understand how the new securities reach the market.

firm commitment basis financial

"purchase on a firm commitment basis"

An agreement in which an underwriter agrees to buy an entire new stock or bond offering from a company and then resell it to the public, taking full responsibility for any unsold shares. Think of the underwriter as a store that buys all the inventory up front: this guarantees the company gets the money and gives investors certainty the deal will happen, while the underwriter’s risk and pricing choices can affect short‑term share availability and price stability.

shelf registration statement regulatory

"pursuant to a shelf registration statement on Form F-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"a prospectus, including a prospectus supplement"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares

YAVNE, Israel, November 3, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,200,000 ordinary shares of MediWound, at a price to the public of $12.50 per ordinary share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about November 5, 2026, subject to satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

MediWound also has granted to the underwriter a 30-day option to purchase up to an additional 180,000 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to MediWound, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriter’s option to purchase additional ordinary shares, are expected to be approximately $15 million.

MediWound intends to use the net proceeds from the offering for working capital and general corporate purposes.

The ordinary shares are being offered by MediWound pursuant to a shelf registration statement on Form F-3 (File No. 333-285908) originally filed with the Securities and Exchange Commission (the “SEC”) on March 19, 2025 and declared effective by the SEC on March 27, 2025. The offering of the ordinary shares is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to, and describing the terms of, the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the preliminary prospectus supplement and accompanying prospectus and the final prospectus supplement and accompanying prospectus may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (212) 856-5711 or e-mail at placements@hcwco.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics for tissue repair. The company’s FDA-approved biologic, NexoBrid^®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, the European Union, Japan, and additional international markets. MediWound’s late-stage development candidate, EscharEx^®, is an investigational therapy for the debridement of chronic wounds, with the potential to become a new standard of care in wound management.

Cautionary Note Regarding Forward-Looking Statements

MediWound cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties, and factors, all of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.

Specifically, this press release contains forward-looking statements concerning the completion of the public offering, the satisfaction of customary closing conditions related to the public offering, the expected gross proceeds from the public offering and the intended use of net proceeds from the public offering, as well as the commercial potential of our products and product candidates. Among the factors that may cause results to be materially different from those stated herein are risks and uncertainties associated with market and other conditions; the risk that the public offering may not be completed on the anticipated terms or at all; the inherent uncertainties associated with the uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our studies of our products and product candidates, including the timing, progress and results of current and future clinical studies, and our research and development programs; the review and approval of regulatory submissions by the FDA, the European Medicines Agency or any other regulatory authority; our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; market acceptance of our products and product candidates; competition risks; and the need for additional financing.

These and other significant factors are discussed in greater detail in MediWound’s annual report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 5, 2026, under the heading "Risk Factors" in the preliminary prospectus supplement and accompanying prospectus relating to the offering, and other filings with the SEC from time to time. These forward-looking statements reflect MediWound’s current views as of the date hereof and MediWound does not undertake, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

MediWound Contacts:
Hani Luxenburg Chief Financial Officer MediWound Ltd. ir@mediwound.com		Daniel Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is MediWound raising in its bought deal offering, and at what price?

MediWound expects approximately $15 million in gross proceeds from an offering of 1,200,000 ordinary shares at $12.50 each. That amount is before underwriting discounts, commissions and offering expenses, and assumes no exercise of the underwriter’s option.

When is MediWound’s ordinary share offering expected to close?

The offering is expected to close on or about November 5, 2026, subject to satisfaction of customary closing conditions.